More about

Yale Cancer Center

News
April 18, 2023
1 min read
Save

AACR names president-elect for 2023-2024

AACR names president-elect for 2023-2024

Patricia M. LoRusso, DO, PhD (hc), has been elected president-elect of American Association for Cancer Research for 2023-2024.

News
March 31, 2023
2 min read
Save

Osimertinib confers lasting DFS benefit in resected EGFR-mutant non-small cell lung cancer

Osimertinib confers lasting DFS benefit in resected <i>EGFR</i>-mutant non-small cell lung cancer

Osimertinib extended DFS and reduced risk for recurrence among patients with resected EGFR-mutated non-small cell lung cancer, according to an updated analysis of data from the phase 3 ADAURA trial published in Journal of Clinical Oncology.

News
March 08, 2023
3 min read
Save

5 women at forefront of oncology digital space

5 women at forefront of oncology digital space

Today marks International Women’s Day.

News
February 18, 2023
3 min read
Save

Sacituzumab govitecan induces response in cisplatin-ineligible urothelial carcinoma

Sacituzumab govitecan induces response in cisplatin-ineligible urothelial carcinoma

SAN FRANCISCO — Sacituzumab govitecan induced response among one-third of platinum-ineligible patients with metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy, according to study results.

News
February 17, 2023
2 min read
Save

Phase 3 trial of pembrolizumab for prostate cancer misses endpoints

Phase 3 trial of pembrolizumab for prostate cancer misses endpoints

SAN FRANCISCO — The addition of pembrolizumab to docetaxel failed to significantly extend survival for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of the randomized phase 3 KEYNOTE-921 trial.

News
February 16, 2023
1 min read
Save

Top in hem/onc: Systemic anticancer treatment; family-friendly medical training policies

Top in hem/onc: Systemic anticancer treatment; family-friendly medical training policies

A recent study published in JAMA Oncology showed the use of aggressive cancer treatment at the end of life has not decreased but rather shifted from chemotherapy to immunotherapy.

News
February 08, 2023
4 min read
Save

Systemic anticancer treatment at end of life shifts to immunotherapy, still raises concern

Systemic anticancer treatment at end of life shifts to immunotherapy, still raises concern

Increased awareness of the quality-of-life harm and financial burden associated with continued cancer treatment at the end of a patient’s life has led professional societies to promote reduced systemic anticancer therapy at this stage.

News
December 28, 2022
3 min read
Save

Cancer organizations seek tighter regulations on electronic nicotine delivery systems

Cancer organizations seek tighter regulations on electronic nicotine delivery systems

American Association for Cancer Research and ASCO have issued a joint policy statement delineating the latest scientific evidence on use of e-cigarettes and other electronic nicotine delivery systems.

News
December 23, 2022
4 min read
Save

BLOG: Navigating complexities of work-life balance

BLOG: Navigating complexities of work-life balance

It was a cold Thursday night in November — the night of Thanksgiving 2022.

News
December 08, 2022
4 min read
Save

Trastuzumab deruxtecan outperforms chemotherapy-based regimens for breast cancer subset

Trastuzumab deruxtecan outperforms chemotherapy-based regimens for breast cancer subset

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer, according to study findings.

View more